3 weeks Ago By ABMN Staff
Vivos Therapeutics ( NASDAQ:VVOS – Free Report ) had its price objective cut by Ascendiant Capital Markets from $6.60 to $6.20 in a report released on Tuesday morning, Benzinga reports.
They currently have a buy rating on the stock. Separately, Alliance Global Partners reissued a “buy” rating on shares of Vivos Therapeutics in a report on Tuesday, April 1st. Check Out Our Latest Analysis on Vivos Therapeutics Vivos Therapeutics Price Performance Vivos Therapeutics ( NASDAQ:VVOS – Get Free Report ) last posted its earnings results on Thursday, March 27th.
The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.
15. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $3.
89 million. Vivos Therapeutics had a negative return on equity of 335.04% and a negative net margin of 86.
19%. On average, sell-side analysts anticipate that Vivos Therapeutics will post -1.79 EPS for the current year.
Institutional Trading of Vivos Therapeutics Hedge funds and other institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC lifted its position in Vivos Therapeutics by 23.8% in the fourth quarter.
Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares during the period. Cutter & CO Brokerage Inc. purchased a new stake in shares of Vivos Therapeutics in the fourth quarter valued at approximately $163,000.
Geode Capital Management LLC grew its holdings in Vivos Therapeutics by 55.6% during the fourth quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock worth $192,000 after acquiring an additional 16,025 shares during the period.
Finally, Anson Funds Management LP purchased a new position in Vivos Therapeutics in the fourth quarter worth $1,041,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.
About Vivos Therapeutics ( Get Free Report ) Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Featured Stories Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
